AI assistant
Sending…
Lexaria Bioscience Corp. — Director's Dealing 2022
Oct 13, 2022
34983_dirs_2022-10-13_5c63540b-5b08-4d79-ab57-166554020e12.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Lexaria Bioscience Corp. (LEXX)
CIK: 0001348362
Period of Report: 2022-10-12
Reporting Person: REESE ALBERT L JR (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-10-12 | Stock Options | $1.96 | A | 3200 | Acquired | 2027-10-12 | Common Shares (3200) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| common shares | 10917 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Options | $4.8 | 2026-02-01 | Common Shares (3400) | 3400 | Direct |
| Stock Options | $3.39 | 2027-03-08 | Common Shares (3400) | 6800 | Direct |
More from Lexaria Bioscience Corp.
Interim / Quarterly Report
2026
Apr 13
Director's Dealing
2026
Mar 18
Delisting Announcement
2026
Feb 6
Regulatory Filings
2026
Jan 28
Declaration of Voting Results & Voting Rights Announcements
2026
Jan 28
Capital/Financing Update
2026
Jan 14
Delisting Announcement
2026
Jan 14
Interim / Quarterly Report
2026
Jan 13
Capital/Financing Update
2025
Dec 29
Regulatory Filings
2025
Dec 19